Skip to content
Sexuality – Lifestyle
Author:
AbbVie Inc.
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
May 22, 2026
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
May 22, 2026
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
May 22, 2026
AbbVie to Present at the Bank of America Securities Healthcare Conference
May 6, 2026
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
May 5, 2026
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
April 30, 2026
AbbVie Reports First-Quarter 2026 Financial Results
April 29, 2026
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
April 29, 2026
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
April 27, 2026
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
April 23, 2026
1
2
3
Next Page
→